AEON Biopharma, Inc. Class A AEON 深 沪
已收盘 02-06 16:00:00 美东时间
1.10
+0.030
+2.80%
华盛通- 最 高1.12
- 今 开1.06
- 成交量 7.31万股
- 最 低 1.01
- 昨 收 1.07
- 总市值 1331.65万
- 52周最高 9.7128
- 市盈率 静 0.02
- 换手率 0.60%
- 52周最低 0.375
- 委 比 0.00%
- 总股本 1210.59万
- 历史最高 1236.24
- 量 比 0.69
- 振 幅 10.28%
- 历史最低 1.01
- 每 手 1
- 风险率 1.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers IO Biotech (NASDAQ:IOBT) stock increased by 76.7% to $0.37 during Thur...
01-23 01:05
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Athira Pharma (NASDAQ:ATHA) stock increased by 30.6% to $5.4 during Th...
2025-12-18 20:05
AEON Biopharma Q3 EPS $(0.39) Beats $(0.43) Estimate
AEON Biopharma (AMEX:AEON) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.43) by 9.3 percent. This is a 96.61 percent increase over losses of $(11.52) per share from the
2025-11-14 21:40
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Mersana Therapeutics (NASDAQ:MRSN) stock increased by 205.0% to $27.05...
2025-11-14 01:06
AEON Biopharma Announces Two Complementary Transaction Of ~$22M, Eliminating Nearly All Debt
AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a BOTOX®
2025-11-13 21:40
美股大行评级 | 最高186美元！戴尔科技或多家机构上调目标价； 高盛上调超微公司目标价至210美元
今日重点评级关注：富国银行：维持Kyverna Therapeutics"超配"评级，目标价从24美元升至27美元；Chardan Capital：维持Oculis Holding"买入"评级，目标价从33美元升至51美元
2025-10-09 10:51
Aegis Capital Reiterates Buy on AEON Biopharma, Maintains $7.2 Price Target
Aegis Capital analyst David Bouchey reiterates AEON Biopharma (AMEX:AEON) with a Buy and maintains $7.2 price target.
2025-10-09 00:43
FDA Schedules Biosimilar Biological Product Development Type 2a Meeting With AEON Biopharma Regarding ABP-450
- Meeting date aligns with prior guidance -- FDA to review AEON's analytical development plan and initial data -
2025-10-01 20:10
港股公告精选｜合景泰富境内债重组获债权人批准 金粤控股上一财年亏损扩大约9成
①合景泰富境内债重组获债权人批准，细节有何看点？ ②金粤控股上一财年亏损扩大约9成，影响有多大？
2025-09-30 20:30
下周备忘
9月29日(周一) 日本7月领先指标终值：初值105.9 日本7月同步指标终值：初值113.3 印度8月工业生产年率：预测升5.5%；前值升3.5% 英国8月抵...
2025-09-26 18:06
